Infection (Keevil) Flashcards

1
Q

What did Hippocrates theorise?

A

That disease might be associated with the physical environment

E.g.
- Touching things

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What did Anton Van Leeuwenhoek do?

A

Developed microscopes

Described the first microorganisms in water and dental plaque in 1683

Named the single cell bacteria and protists as “Animalcules”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What did Edward Jenner do?

A

Pioneered clinical trial for vaccination to control spread of smallpox using the similar cowpox

Jenners work influenced many others, including Louis Pasteur who developed vaccines against rabies and other infectious diseases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What did Ignas Semmelweis do?

A

Pioneered hand washing to help prevent the spread of septic infections in mothers following birth

Infection rates in Vienna Obstetrics Clinic decreased from 18% to 2%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What did John Snow do?

A

Father of epidemiology

Careful mapping of cholera cases in London during cholera epidemic of 1854

Traced source to a single well on Broad Street, Soho that had been contaminated by sewage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What did Louis Pasteur do?

A

Disproved spontaneous generation;
fermentation is caused by microbial
growth

Nothing grew in boiled broths when a filter in place or tortuous tube, therefore living organisms that grew in such broths came from outside, as spores on dust, rather than being generated within the broth.

Developed weakened anthrax vaccine, immunised cattle; rabies etc

Often regarded as the father of Germ Theory and Bacteriology, together with
Robert Koch

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What did Joseph Lister do?

A

Pioneered antiseptic surgery

Most had assumed that chemical damage from exposure to bad air was responsible for infections in wounds

Pasteur suggested three methods to eliminate the micro-organisms responsible for gangrene: filtration, exposure to heat, or exposure to chemical solutions

Lister confirmed Pasteur’s conclusions and then used carbolic acid (phenol) to sterilise surgical instruments and clean wounds; reducing post-operative infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What did Robert Koch do and what are his postulates?

A

He came up with a way to define a pathogen

Postulates:

1) Isolate the organism from every case of disease

2) Propagate in pure culture in vitro

3) Reproduce disease by exposing suitable host to organism

4) Re-isolate the organism

If these are met, can be defined as pathogen

Turned out to not be accurate, as chronic or minor conditions, multiple causes and pathogens that arent able to be grown in the lab were hard to define with these postulates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What did Hans Christian Gram do?

A

Pioneered Gram stain

Developed to detect bacteria in stained lung sections in the Berlin hospital morgue but became universal method of differentiating bacteria

Based on the chemical and physical properties of their cell walls. Detects peptidoglycan, a thick layer in Gram-positive bacteria to which crystal violet becomes trapped in the presence of iodine; ethanol dehydrates/stabilises this but washes CV+I-out of Gram-negative bacteria. Counterstain.

  • Gram positive gives a purple/blue color,
  • Gram negative results in a pink/red color.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Who is Typhoid Mary?

A

She is the first documented case of ASYMPTOMATIC carrier of typhoid fever

She caused multiple typhoid fever outbreaks over many years when she worked as a cook, she was never ill and completely well but carried typhoid fever asymptomatically

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are some host defences against pathogenic attachment?

A

Microbes can be rinsed away from epithelial surface by host secretions

Also, ciliary activity in respiratory tract can remove pathogens

We can also produce secretory immunoglobulin (IgA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are some microbial strategies for attachment?

A

They can bind firmly to epithelial surface (and if relevant, interfere with ciliary activity) via surface molecules on the microbe attaching to receptor on epithelial cell (and, if relevant, production of ciliotoxic/ciliostatic molecule)

They can also inactivate IgA via production of IgA proteases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are some examples of pathogen attachment mechanisms

A

Enteropathogenic E. coli (EPEC) adhering to a tissue culture cell. EPEC are closely related to enterohaemorrhagic E. coli but don’t express a Shiga-like Toxin

Type 1 fimbriae on E. coli. These filamentous appendages bind to D-mannose residues on the eukarvotic cell surface. They are often termed ‘mannose-sensitive’ fimbriae as the presence of D-mannose in the growth medium prevents binding.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is a host defence against pathogenic invasion?

A

The host cell membrane poses barrier to intracellular microbe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are some microbial strategies of pathogenic invasion?

A

Traverse host cell membrane via fusion proteins in viral envelope

Endure or trigger uptake by phagocyte and resist killing
via injecting proteins that trigger uptake and/or block intracellular killing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are some pathogenic invasion examples?

A

The first image is of a transmission electron microscope image of a tissue culture cell line, infected with human immunodeficiency virus (HIV)

HIV particles are 90-120 nm in diameter. The virus attaches via the CD4 molecule on the surface of a lymphocyte, which acts as a surface receptor for HIV.
After fusion of the virus envelope with the membrane, the nucleocapsid, containing the RNA, is carried into cytoplasm by endocytosis.

The second image is of salmonella associated with membrane ruffles on the surface of an epithelial cell.

After initial adherence, this pathogen injects proteins into the host cell (e.g. SipA to staple actin filaments together, rearrange cell and engulf bacterium) to bring about its uptake - a process termed invasion. Looser actin filaments also surround stabilize the vacuole for intracellular survival.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are some host defences against intracellular survival of pathogens

A

Ingestion and killing of microbe by a phagocyte

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are some pathogenic strategies of intracellular survival?

A

STRATEGIES:

Block phagocyte chemotaxis;

Kill phagocyte before or after phagocytosis; inhibit phagocytosis;

Inhibit lysosome fusion; resist killing and multiply in phagocyte

MECHANISMS:

Release leucocidins, antiphagocytic haemolysins etc.

Use of microbial cell wall or capsule components to inhibit phagocytosis

Intracellular microbe inhibits one or more cell components needed for fusion of phagosome with lysosome

Diversion of toxic compounds away from subcellular compartment containing microbe

Can escape from phagosome into cytosol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is a salmonella intracellular survival example?

A

Salmonella is a facultative intracellular pathogen that survives and even replicates within macrophages.

Transposons bearing reporter genes can be used to probe the intracellular like of such pathogens.
In this experiment a transposon expressing Green Fluorescent

Protein as a reporter has inserted into a Salmonella gene that is induced when the bacteria enter macrophages.

Thus, the Salmonella cells within macrophages fluoresce (GREEN) external Salmonella (RED) are also visible.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is a listeria intracellular survival example?

A

LEFT PANEL:
- Intracellular Listeria monocytogenes (RED) escape from their phagosomes into the cytosol. They are then able to catalyse the polymerisation of host F-actin at one of their poles using their Act surface protein; actin-based motility by “comet tails”. This ‘rocket’ propulsion mechanism pushes the bacterial pathogen towards the cytoplasmic membrane which eventually ruptures allowing their spread to a neighbouring cell. Mimics neutrophil actin rearrangement pseudopodia movement.

RIGHT PANEL:
- Vaccinia virus (RED) also polymerises actin in order to move within a cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the importance of Fe(III) in intracellular survival?

A

The host restricts Fe(III) to pathogens

The microbe pathogens scavenges iron in competition with the host.

Microbial mechanisms:

Microbe secretes molecules - siderophores - that bind Fe(III) in the host with extremely high affinity

The complexes are imported to the cytosol where the captured iron is released

Iron is essential to majority of life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What do pathogens do to overcome the host defence of production reactive oxygen and nitrogen species to pathogen intracellular survival

A

Microbe avoids oxidative burst or removes ROS
and RNS

Microbial mechanisms:

Microbe diverts vesicles bearing NADPH oxidase so that they don’t fuse with phagosome;

They produce enzymes (catalse; superoxide dismutase etc.) to inactivate ROS and RNS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

How do pathogens combat production of complement and antimocrobial peptides in extracellular survival?

A

Microbes alter their cell surfaces; inactivate complement; or bind complement non-productively

Microbial mechanisms:

Sialylation of bacterial cell surface or alterations in LPS structure; production of proteases

C3b receptor on microbe competes with that on phagocyte to hinder production of membrane attack complex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

How do pathogens combat production of antimocrobial antibodies in extracellular survival?

A

Microbes can destroy antibody

They can
- Prevent induction of protective antibody
- Express F receptor
- Prevent antibody (or complement) from binding near cell surface
- Avoid immune recognition

Microbial mechanisms:
- Secretion of IA protease
- Infection of lymphoid cells
- Bind antibody so that it is oriented 180° from normal
- Produce long chain LPS to keep antibodies and complement at ‘arms length’
- Acquire coating of host molecules (e.g. fibronectin).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

How do pathogens combat antimocrobial cell-mediated response in extracellular survival?

A

Invasion of T cells to block their function or to kill them; switch on T cells or B cells non-specifically, or non-productively

Microbial mechanisms:
- Virus envelope component binds CD4 on helper
T cell surface
- Polyclonal activation of B cells
- Polyclonal activation of T cells by release of T cell mitogens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

How do pathogens combat antimocrobial immune response in extracellular survival?

A

Infect glands or epithelial surfaces that are relatively inaccessible to circulating antibody or immune cells

Suppress immune responses

Vary microbial antigens either in a single host or during spread in host community

Microbial mechanisms:
- Trophism for cells in glands or on surfaces
- Invade immune tissues
- Switch on different surface antigens
- Use of mutation and/or genetic recombination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q
A

Structure of Cholera Toxin (CT):
- The A subunit is enzymatically active and consists of two parts: A1 and A2
- The B subunit is responsible for binding to the host cell receptor and is composed of five identical B subunits

The B subunit pentamer binds specifically to the GM1 ganglioside receptor on the surface of intestinal epithelial cells

Retrograde endocytosis occurs where B subunits are left behind and the A subunits enter the cell

A1 causes a large increase in adenylate cyclase activity

This causes a very large increase in cAMP activity in the cell

This causes massive loss of water and solutes out of the cell, causing diarrhoea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

GM1 receptor mechanism

A

The GM1 receptor, a seven-loop transmembrane receptor, has an associated molecule called Gsα

Normally, Gsα diffuses along the cell surface and binds to adenylate cyclase, suppressing its activity

However, when cholera toxin binds to this complex, it overcomes the suppression

This results in a large increase in cAMP concentration, converting ATP into cyclic AMP.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What are some E. Coli type mechanisms?

A

Noninflammatory diarrhoea:

  • Enterotoxigenic E. coli (ETEC) - attach to small intestinal mucosa and elaborate one or both of heat labile and heat stable toxins
  • Enteropathogenic E. coli (EPEC) - attach firmly to intestinal mucosa causing dissolution of brush border by inducing vesiculation of microvilli: attaching-effacement.

Inflammatory diarrhoea:
- Enteroinvasive E. coli (EIEC) - attach to colonic enterocytes, penetrate by an endocytotic mechanism and replicate therein. Causes necrosis and stripping of large areas of colonic mucosa and a dysentery.

  • Enteroaggregative E. coli (EAggEC) - damage and blunt colonic villi by haemorrhagic necrosis, precise pathogenic mechanisms unclear.
  • Enterohaemorrhagic E. coli (EHEC) - produce attaching-effacement to terminal ileal and colonic mucosa; release shiga-like toxins 1 or 2 which kill colonic enterocytes and produce haemorrhagic colitis; but diarrhea maybe caused by bacterial invasion of host cells and interference with normal cellular signal transduction, rather than toxin production.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Key features of Enterohaemorrhagic E. Coli

A

Major food-borne infectious pathogen

Causes diarrhoea, haemorrhagic colitis, haemolytic uraemic syndrome

Destruction of red blood cells (hemolytic anemia), destruction of platelets (responsible for clotting; low counts = thrombocytopenia), and acute renal failure.

Most common cause of acute renal failure in children

Significant health risk due to disease severity, lack of effective treatment and the potential for large-scale outbreaks from contaminated food

950 reported cases in UK in 2005 (36% increase on previous year); USA estimates: ~75,000 p.a.

Typically caused by E. coli 0157:H7 serovar

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Enterohaemorrhagic E. Coli mechanism?

A

EHEC produce several toxins - major one is Shiga-like toxin (SLT)

Adhere to enterocytes in large intestine and remove (‘efface’) microvilli

Trigger remodelling of cytoskeleton and rearrangement of the actin filaments underneath the bacterial adhesion site resulting in a deformation of microvilli into a dysfunctional pedestal-like structure designated the site of attachment and effacement

32
Q

What are pathogenicity islands?

A

Genetic studies show EHEC has a >30 kb cluster of pathogenicity genes not present in E. coli
K-12

Such clusters, termed Pathogenicity Islands, are common in disease-causing bacteria.

Pathogenicity islands are acquired by horizontal gene transfer from other bacteria and typically have a C + G content that differs from the rest of the genomic DNA

33
Q

What is Locus of Enterocyte Effacement (LEE)

A

Major pathogenicity island in EHEC is termed Locus of Enterocyte Effacement (LEE)

LEE encodes proteins that form a specialized T3SS secretion system that injects EHEC proteins such as Tir (translocated intimin receptor) into the host cell as well as other the injected proteins e.g. EspD facilitates host pore formation.

34
Q

What are shiga-like toxins?

A

The major toxin produced by EHEC

Two types (St×1 and St×2) but both closely resemble Shiga toxin produced by
Shigella - have an enzymatic A subunit and 5 identical B subunits

A subunit inhibits protein synthesis - cells are unable to recover once toxin is removed. A subunit is an N-glycosidase - specifically depurinates adenosine 4324 in 28S rRNA

B subunits bind to ceramide host cell receptors, e.g globotriaosylceramide (Gb3): present in greater amounts in renal epithelial tissues (explains renal toxicity of Shiga toxin); also found in CNS neurons and vascular endothelium (blood vessels) (lead to neurotoxicity). Gb3 not present in human intestine.

35
Q

History and incidence of aids?

A
  • The story of AIDS began in 1981 when a cluster of unusual diseases was observed in certain groups of people. The two main diseases were:
  • pneumonia caused by a yeast, Pneumocystis carinii,
  • and an unusual tumour called Kaposi’s sarcoma caused by human herpes virus 8
  • Initially in homosexual men but later the same symptoms appeared in intravenous drug users and haemophiliacs who were injecting blood-clotting factors.
  • This pattern of disease occurrence suggested that a transmittable agent was responsible for the diseases. Unusual aspect of these diseases was they were only seen in immunosuppressed people and not in people with a fully functioning immune system.
  • The observation that individuals with these diseases had low numbers of
    CD4 T cells was consistent with immunosuppression
  • 1982 the term acquired immunodeficiency syndrome, or AIDS, was used by the Centers for Disease Control (CDC) in Atlanta to describe the disease.
36
Q

HIV History

A
  • 1983 virus causing isolated from lymph node of an infected individual by Luc
    Montagnier’s group in Paris and was called the human immunodeficiency virus, or HIV for short.
  • Second strain of HIV was identified in 1986; called HIV-2 and first strain was renamed HIV-1.
  • HIV-1 and HIV-2 differ in their virulence and geographical location. HIV-2 is less virulent than HIV-1 and is found primarily in western Africa.
  • Genetic studies showed that both HIV-1 and HIV-2 are natural viruses of primates that have jumped species to infect humans. HIV-1 came from chimpanzees and HIV-2 from the sooty mangabey.
  • Both animals are killed for food and assumed that it was during this process that the virus initially infected humans.
  • HIV -1 and HIV-2 do not cause immunosuppression in chimpanzees or sooty mangabeys; only when virus crossed into humans did it cause the profound immunosuppression seen in AIDS.
37
Q

Incidence of AIDS and HIV today

A

Estimated since 1981 over 75 million people worldwide were infected with HIV and over 32 million died (43% dead); 2 million died in 2007 and 2008.

The highest rate of increase in HIV infection is seen in sub-Saharan Africa; estimated 20-40% of young adults are infected.

Thus life expectancy in sub-Saharan Africa almost halved; it is now in the 30s-40s instead of approaching 70, the estimated life expectancy if AIDS pandemic had not occurred.

Pattern of spread in Africa appears to be primarily by heterosexual contact and has a similar incidence in men and women.

By contrast, spread in Europe, the USA and Oceania is still mostly among ‘high-risk’ groups such as homosexuals and intravenous drug users; much more prevalent in men than women.

However, signs in USA that pattern of spread is changing, with more women being infected.

38
Q

HIV Strains and variants

A

Some of the terminology used to describe HIV can be confusing.

The two 1 strains of HIV are called HIV-1 and HIV-2. Also many different subtypes of HIV-, 1 so vaccines needed to protect against all subtypes.

Also, HIV has very high mutation rate, giving rise to different forms of the virus known as variants.

Variants important because, as described later, they differ in which cell types they can infect.

Although different strains, subtypes and variants of HIV, very similar in structure and replication; therefore will be described together and referred to collectively as HIV.

39
Q

HIV Structure?

A

HIV retrovirus (lentivirus family):

Contains RNA as genetic material.

HIV genome contains 2 molecules of single-stranded RNA, each bound by a molecule of reverse transcriptase.

Within genome are also a p10 protease and a p32 integrase.

Genome is surrounded by nucleocapsid consisting of inner layer of protein p24 and outer layer of protein p17 (both part of Gag (group specific antigen) polyprotein complex).

Outer portion of virus consists of lipid envelope derived from host cell membrane

Contains two viral proteins, gp120 and gp41, which collectively are called viral envelope proteins.

40
Q

HIV genome structure

A

LTR-long terminal repeats; repetitive sequence of bases

gag-group specific antigen gene, encodes viral
nucleopcapsid proteins: p24, a nucleoid shell protein, MW=24000; several internal proteins, p7, p15, p17 and p55.

pol-polymerase gene; encodes the viral enzyme, protease (p10), reverse transcriptase (p66/55; alpha and beta subunits) and integrase (p32).

env-envelope gene; encodes the viral envelope glyocproteins g120 (extracellular glycoprotein, MW=120 000) and gp41 (transmembrane glycoprotein, MW=41000).

tat: encodes transactivator protein

rev: encodes a regulator of expression of viral protein

vif: associated with viral infectivity

vpu: encodes viral protein U

vpr: encode viral protein R

nef: encodes a ‘so-called’ negative regulator protein

41
Q

What does HIV GAG encode ?

A

HIV GAG encodes structural capsid proteins, produced as a GAG precursor polyprotein, which is processed by viral protease.

p17 - Matrix protein - 131 amino acids (residues 1 - 131)

p24 - Core Antigen capsid protein - 231 amino acids (residues 132 - 362)

p7 - Nucleo-Capsid protein - 55 amino acids (residues 377 - 431)

p6 - 52 amino acids (residues 448 - 499)

p2 - 14 amino acids (residues 363 - 376)

p1 - 16 amino acids (residues 432 - 447)

42
Q

HIV Particle structure

A

HIV is an enveloped retrovirus and has two single-stranded RNA molecules as its genetic material

The RNA is associated with reverse transcriptase, integrase and polymerase enzymes, which are necessary for viral DNA and RNA synthesis

Surrounding this is the nucleocapsid, which consists of an inner layer of p24 protein and an outer layer of p17 protein

The outer portion of the virus consists of a lipid layer derived from the host cell into which is inserted the viral gp41 envelope protein

Each gp41 protein molecule is associated with a molecule of the gp120 envelope protein.

43
Q

What is the replication cycle of HIV?

A

Like any other virus, HIV must infect a host cell before replicating, with
the viral progeny leaving the cell to infect others.

HIV infects glycoprotein-CD4+ cells (helper T cells recognize antigens on the surface of a virus-infected cell and secrete lymphokines that stimulate B cells and killer T cells; BUT helper T cells are infected and killed by the AIDS virus).

In addition to CD4 T cells, monocytes and dendritic cells also express CD4, although at lower levels than T cells.

Two stages to viral infection: binding to the host cell, and fusion with the cell membrane to allow the virus to enter the cell

Initial binding to host cell involves gp120 protein on surface of HIV particle binding to CD4 on host cell surface.

44
Q

Life cycle of HIV?

A

1) Binds to CD4 +ve cells through gp120 to CD4; interactions between virus and chemokine co-receptors.

2) Nucleocapsid enters the cell, unfolds, releasing viral RNA, which is reverse-transcribed to DS DNA.

3) The viral DNA integrates in the host genome, where it lies dormant as a provirus.

4). Following cell activation, viral DNA directs the transcription of viral RNA.

5) Viral proteins are translated from the RNA.

6) Viral proteins and single-stranded viral RNA assemble to form new viral particles.

7) Virus buds from the cell, picking up some of cell membrane, complete viral particles can infect other cells.

45
Q

HIV infected dendritic cell mechanism

A

An HIV-infected dendritic cell shoots out thin projections called filopodia (red) with virus particles (white) at their ends. Actin filament rearrangement projects filopodia in a waving arc towards T-cells at um/sec, faciltating 800 dendtritic cell - T-cells interactions/hour.

46
Q

HIV Binding mechanism

A

gp160, is a fusion glycoprotein to overcome the energy barrier associated with the fusion of two membranes. gp160 is in trimer formation, meaning three molecules of gp160 are arranged together, often called “spikes”

During early fusion process, gp160 cleaves into gp41, considered the transmembrane glycoprotein and gp120 (considered the surface glycoprotein

However, gp41 and gp120 remain in trimer formation and noncovalently attached to each other. In this configuration, gp41 is thought to be in high energy state, with its fusion peptide buried inwards.

Fusion peptide is molecule composed of linked amino acids.

gp120 binds onto host cell surface to the receptor CD4 causing a conformational or structural change of gp120, which in turn, allows gp120 to bind again, this time to a chemokine coreceptor, usually CXCR4 or CCR5.

gp41 is released from its high energy state and the previously buried fusion peptide springs out towards the host cell membrane, bridging the divide between the virion and the host cell membrane.

after chemokine coreceptor binding, gp120 is thought to disassociate away. At this point, glycoprotein 41 transiently becomes an integral component of two membranes: the viral membrane in which it is
anchored and the cellular membrane that it has gaffed

47
Q

CCR-5 importance in binding

A

CCR-5 gene has two alleles, one is mutated in 10% of Northern Europeans and results in a non-functional form of the CCR-5 protein which delays progression to AIDS.

Approximately 1% of Caucasians are homozygous for the null allele and therefore express no functional CCR-5 protein. These individuals are resistant to infection with HIV.

Since their expression of CXCR-4 is normal, suggests that initial infection is by M-tropic variants using the CCR-5 receptor. Indeed isolates of HIV in recently infected individuals are predominantly M-tropic.

Emergence of T-tropic variants is often a sign of rapid progression to AIDS.

Following binding of Gp120 to CD4 and the relevant chemokine receptor, gp41 mediates fusion between the viral envelope and host cell membrane, allowing viral nucleocapsid to enter the cell.

48
Q

HIV replication

A

Once inside the cell virus nucleocapsid is removed and reverse transcriptase copies the RNA into double-stranded DNA (poor fidelity, with no proof reading ability, ~10 mistakes per replication round; so many mutations arise).

Viral DNA integrates into the host cell DNA, where it is known as a provirus (RNase H degrades the copied RNA template).

This stage of viral infection is known as latent stage and virus can lie dormant for a long time.

Virus production is initiated by cellular transcription factors e.g. NF-kB which is upregulated when T-cells become activated

Viral RNA is transcribed from proviral DNA and viral proteins are translated using host cell protein synthesis machinery.

Viral proteins and RNA assemble into particles that bud from the cell, taking some of the host cell membrane to form the viral envelope.

49
Q

Signs of HIV

A

Most people show no symptoms immediately after infection

But about 15% demonstrate symptoms reminiscent of influenza:

these include
- fever,
- malaise,
- aching muscles,
- sore throat and
- swollen lymph nodes.

Some people also develop swollen lymph nodes without any other clinical symptoms.

Following infection, antibodies to HIV antigens are produced: a process called seroconversion.

Detection of antibodies to HIV is used to test for infection.

50
Q

Latency of AIDS

A

This period is generally asymptomatic although about 33% of infected people will have swollen lymph nodes.

The average time from infection to development of AIDS is about 10 years

But length of the “latency” period is extremely variable, lasting less than a year in some people and upwards of 15 years in others.

Not clear whether everyone infected with HIV will inevitably develop AIDS.

51
Q

Development of AIDS

A

End of “latency” period is accompanied by emergence of various symptoms that indicate progression to AIDS without treatment.

Symptoms include weight loss, night sweats, fever and diarrhoea.

Also infections such as oral candidiasis, herpes simplex and shingles caused by minor opportunistic infectious agents.

AIDS defined clinically by appearance of major opportunistic infections or by a drop in the CD4 † celi count to below 200 cells/ul of blood.

Without treatment AIDS invariably leads to death. Death is caused by combinations of the infections although some infections are more prominent according to geographical location.

In Europe, the USA and Oceania the commonest infection is pneumonia caused by Pneumocystis carinii.

In Africa and Asia, infections such as Cryptosporidium, a protozoan that causes severe diarrhea and weight loss, and Mycobacterium tuberculosis are more common.

52
Q

Lymph nodes in HIV

A
  • Many HIV+ individuals develop swollen lymph nodes during initial infection
  • Can persist even during the clinically latent phase.
  • Histological examination of lymph nodes shows:
  • increasing disruption of normal lymph node architecture,
  • influx of CD8 T cells
  • eventual loss of germinal centres.
53
Q

Dendritic cells role in HIV infections

A
  • Dendritic cells patrol tissues, on the lookout for microbial invaders.
  • When encounter a pathogen chop it up into tiny pieces and carry samples of it to local lymph nodes.
  • There, they display their finds to the CD4 T cell, which then mounts full-fledged immune response against the invader.
  • Lymph node inflammation.
  • Unfortunately, HIV exploits the DC surveillance network to its own advantage: HIV is picked up by DCs that patrol mucosal tissues, but avoids being killed by them, and instead hitches a ride to lymph nodes before transfer to the CD4 T cell. Until now, not clear how DCs recognize HIV for uptake a mystery that’s now been solved.
  • Sialyllactose head on GM3 ganglioside (glycosphingolipid) exposed on
    HIV membrane is recognised by DC and virus is taken in.
54
Q

How does loss of CD4 T cell function occur?

A

As infection progresses HIV+ individuals show loss of CD4 T cell function that cannot be explained simply on basis of reduced CD4 T cell numbers and is somehow associated with the effects of the vIrus.

Transplantation recipients taking immunosuppressive drugs can show drops in CD4 T cell numbers similar to those seen in HIV+ individuals but the transplant recipients demonstrate much better
CD4 T cell function.

Reasons for loss of CD4 T cell function are not clear. One consequence of loss of Th activity is reduced ability to mount a delayed-type hypersensitivity reaction

As infection progresses ability to generate antibody responses is also lost.

55
Q

Antibody abnormalities in HIV infected patients

A
  • Somewhat paradoxically, HIV+ individuals can demonstrate increased total levels of serum lg despite the impaired ability to generate specific antibody responses.
  • Again the basis for this is not clear but thought to reflect abnormalities in normal regulation of immune responses caused by the virus.
  • Possibly also related to generalised immune dysfunction, HIV+ individuals can show increased production of autoantibodies to antigens such as:
  • red blood cells,
  • spermatozoa or
  • myelin (a component of nerve sheaths)

And may suffer from flare-ups of allergies such as eczema.

56
Q

Initial T cell response to HIV infection

A
  • Immediately following infection with HIV there is a period of rapid viral replication resulting in high levels of virus in the blood (viraemia)
  • HIV is an intracellular pathogen and as such would be expected to stimulate a strong CD8 cytotoxic T cell response and possibly a delayed type hypersensitivity response, as well as production of antibody.
  • In fact strong antibody responses to gp120 envelope protein and the p24 protein of the nucleocapsid (also known as a Gag) are seen soon after viral infection
  • Also a powerful CD8 cytotoxic T cell against gp120, p24 and some of the proteins that make up reverse transcriptase (p01 antigens).
  • Combined antibody and cytotoxic T cell response is extremely effective and eliminates more than 99% of the virus.
  • Following this strong response the disease usually enters the latent stage.
57
Q

What did treatment of infected individuals with drugs that prevented HIV from infecting new cells show?

A
  • (i) the immune svstem was eliminating up to 30% of the total viral load every day but that in the absence of these drugs the virus replicated at an enormous rate and the eliminated virus was replaced
  • (ii) up to 2 x 10^9 CD4 T cells were destroyed every day but most of these were replaced by the immune system so that the overall CD4 levels in the blood declined only very slowly.
58
Q

What is apparent about the latent stage of HIV infection?

A

Now appears that latent stage of HIV infection may be clinically latent but actually represents a very dynamic situation with high viral destruction and replication and extensive CD4 T cell destruction and replacement.

59
Q

Reasons for HIV survival in immunological onslaught

A
  • Has a very high replication rate - main reason why the virus is not totally cleared.
  • Can hide as provirus where not detectable by the immune system.
  • Has very high mutation rate, so that antigens to which antibody and CD8 T cells have been made mutate and are no longer recognised by the immune system. Antibodies and CD8 Tcs are made against the mutated antigen but this can mutate again and so the process of evading the immune response goes on and on.
60
Q

How are CD4 T cells lost?

A
  • Cause of CD4 T cell loss is thought to be a combination of direct killing by the virus and destruction of virally infected cells by the immune system.
  • CD4 cells that are infected by the virus express viral antigens on their surface. These mav be viral peptides presented by class I MHC or may be soluble gp120 bound to CD4 on the T cells.
  • HIV+ individuals can have large amounts of soluble gp120 in their blood and lymph, which will bind to CD4.
  • Because of the expression of viral antigen, CD4 T cells can be killed in a number of ways
60
Q

What are the 4 main ways of CD4 T cell killing?

A

(a) HIV may directly cause lysis of CD4 T cells.

(b), (c) Infected cells bearing HIV antigens may be killed by antibody and complement (b) or killed by antibody-dependent cell-mediated cytoxicity (c).

(d) HIV-infected cells presenting HIV peptides on their class I MHC molecules may be killed by CD8
T cells

61
Q

Apoptosis versus Pyroptosis CD4 T Cell
Killing Mechanisms

A

When HIV productively infects the few permissive CD4 T cells present in spleen, death occurs through apoptosis mediated by the enzyme caspase-3.

But when HIV abortively infects nonpermissive CD4 T cells, (fail to complete reverse transcription i.e. accumulation of incomplete HIV transcripts triggers cell death) death occurs by pyroptosis, which depends on activation of caspase-1.

Approx. 95 percent of CD4 T cell death in lymphoid tissues is driven by caspase-1-mediated pyroptosis.

So, most CD4 T cells in lymphoid tissues, despite ability to resist full infection by HIV, respond to presence of viral DNA by sacrificing themselves via pyroptosis-a highly inflammatory form of cell death that lures more CD4 T cells to the area, thereby creating a vicious cycle that ultimately wreaks havoc on the immune system.v

62
Q

What is VX-765

A

VX-765 efficiently blocks CD4 T-cell death in HIV-infected tonsillar and splenic lymphoid tissues. No toxicity was observed at any of these drug concentrations.

Pyroptosis in HIV-infected lymphoid tissues may establish a chronic cycle of CD4 T-cell death and inflammation, which attracts new CD4 T cells and ultimately contributes to disease progression and tissue damage

1Inhibitors of caspase 1 such as VX-765 may inhibit pyroptosis in a manner that both preserves CD4 T cells and reduces inflammation.

63
Q

Pyroptosis CD4 T Cell locations

A
  • Progression to AIDS driven by CD4 T-cell depletion, mostly involving pyroptosis elicited by abortive HIV infection of CD4 T cells in lymphoid tissues.
  • Inefficient reverse transcription in these cells leads to cytoplasmic accumulation of viral DNAs that are detected by the DNA sensor
    IFI16, resulting in inflammasome assembly, caspase-1 activation, and pyroptosis.
  • BUT peripheral blood-derived CD4 T cells naturally resist
    Pervert HiV.: Preverse franscripts and lowerne ita expression. in
  • However, when co-cultured with lymphoid-derived cells, blood-derived CD4 T cells become sensitized to pyroptosis, likely recapitulating interactions occurring within lymphoid tissues.
  • Sensitization correlates with higher levels of activated NF-KB, IF|16 expression, and reverse transcription.

Thus, lymphoid tissue microenvironment encountered by trafficking CD4 T lymphocytes dynamically shapes their biological response to HIV.

64
Q

CD4 T cell death overview

A
65
Q

Chemotherapy of HIV

A

High mutation rate of HIV is not only a problem for the immune system; also a problem in trying to treat HIV+ individuals with antiviral drugs.

First anti-HIV drug was zidovudine (AZT), a reverse transcriptase inhibitor introduced in 1987.

Although it inhibited replication of HIV, virus very quickly mutated and became resistant to the drug.

Now three types of anti-HIV drug in use clinically.

Combinations of two, or preferably three, drugs are of longer clinical benefit because there is less chance of the virus mutating to become resistant to three drugs at once.

66
Q

What are the 3 main types of HIV inhibitors?

A
  • nucleoside analogue reverse transcriptase inhibitors, - -
  • non-nucleoside analogue reverse transcriptase inhibitors
  • HIV protease inhibitors
67
Q

Mechanism of the reverse transcriptase HIV inhibitors

A

Two types of reverse transcriptase inhibitor act in different ways to inhibit the reverse transcriptase; therefore complement each other’s action:

Nucleoside/Nucleotide analogues lack a 3’-hydroxyl group on the deoxyribose moiety. Following incorporation the next incoming deoxvnucleotide cannot form the next 5’-3 ‘ phosphodiester bond needed to extend the DNA chain. Thus, viral DNA synthesis is halted, a process known as chain termination. All are classified as competitive substrate inhibitors.

Non-nucleoside analogues block reverse transcriptase by binding at a different site on the enzyme, compared to NRTIs and NtRTIs. NNRTIs are not incorporated into the viral DNA but instead inhibit the movement of protein domains of reverse transcriptase that are needed to carry out the process of DNA synthesis. Classified as non-competitive inhibitors.

Reverse transcriptase inhibitors interfere with the synthesis of viral cDNA from the viral RNA.

Protease inhibitors inhibit the cleavage of viral polyproteins into viral proteins.

Without the viral proteins replication cannot occur.

68
Q

Protease inhibitors HIV inhibitor mechanism

A

Protease inhibitors inhibit the active site of the HIV aspartic protease, used to cleave a number of viral precursor polyproteins to produce many HIV proteins and enzymes. Peptide linkage -ÑH-CO- is replaced by uncleavable hydroxyethylene group ( CH2-CH(OH)-)

Without protease activity the virus can not replicate

69
Q

Combination chemotherapy mechanism

A

Combination chemotherapy usually consists of two reverse transcriptase inhibitors and a protease inhibitor.

Can be very effective at lowering levels of virus and raising CD4 T cell levels and results in significant clinical improvement so that many AIDS patients are able to leave the AIDS clinic and return home.

New therapy is also thought to be responsible for the sharp drop in death from AIDS seen in the USA since 1996. However, there are problems with combination therapy.

There is considerable toxicity, especially to the bone marrow and gut, which means some people cannot take the drugs.

Regime for taking the drugs is complicated and intrusive to a normal lifestyle.

Some of the drugs have to be taken with food and some without, and some drugs cannot be taken within a certain time period of each other.

Finally the drug treatment is very expensive - about $15,000 a year - so that it is not readily available in the countries that need it the most.

Therapy successfully suppresses HIV but is not cleared from the body.

70
Q

What is PA-457?

A

The drug PA-457 disables HIV by destroying the protein shield protecting its RNA

Normally, the capsid protein is clipped apart from a major structural protein called the gag protein, and is then assembled into a cone. PA-457 stops it being clipped off, causing it to form a leaky sphere that leaves the core
RNA exposed

71
Q

What are the two types of HIV vaccines being considered

A

Prophylactic vaccines.

  • Aim of these vaccines was to provide protection to individuals who were not infected with the virus.
  • Thus, the aim was the same as for vaccines against other infectious agents such as measles, mumps, polio, smallpox, etc.

Therapeutic vaccines.

  • AIDS was initially considered a disease of immunosuppression where HIV - infected people did not make a very good response against the virus.
  • Therefore thought it might be possible to boost the immune response of HIV-infected people so that they could mount a response and clear the virus.
  • With the current appreciation that most HIV-infected people make a very strong response against the virus it is not so clear how effective this approach might be.
72
Q

Immunological issues for prophylactic vaccines?

A

Main immunological issues concerning development of an HIV vaccine are:

  • which of the many different current approaches to vaccine development to use, given the many subtypes and variants and the mutation rate of the virus
  • what type of immune response to try and stimulate
  • additionally there are no good animal models of HIV
73
Q

Logistical issues for prophylactic vaccines?

A
  • Main logistical problems are in testing the vaccines.
  • Traditionally vaccines were developed against acute diseases that often occurred in waves or epidemics (e.g. measles or mumps) and had a low mortality rate.
  • Therefore comparatively straightforward to vaccinate a section of the population and see whether these people were protected from the disease compared with non-vaccinated individuals.

Possible this way to get an answer to the effectiveness of the vaccine in a relatively short time.

  • Because AIDS is a chronically progressive disease the conventional approach would take many years to give an answer - too long for most people to wait.
  • A number of vaccines in clinical trials at present using DNA, recombinant and antigen/peptide approaches, although none has demonstrated convincing protection so far.
74
Q

What are broadly neutralising human monoclonal antibodies?

A

They are naturally occurring, broadly neutralising HIV antibodies that mimic the CD4 binding site on the envelope spike that the virus uses to enter and infect its host cells

They do not work to combat HIV due to high mutation rate

75
Q

HIV Summary in total

A

AIDS as a disease was first identified in 1981 in groups of high-risk individuals: homosexual men, intravenous drug users and haemophiliacs.

Currently estimated that 30 million people are infected with the AIDS virus.

Virus causing AIDS was isolated in 1983 and called the human immunodeficiency virus (HIV). A second strain, called HIV-2, was identified in 1986.

HIV is a retrovirus, i.e. its genetic material consists of RNA. It infects CD4+ cells, mainly CD4 T cells but also monocytes and dendritic cells.

Clinically HIV infection is characterised by the development of opportunistic infections, especially with the yeast Pneumocystis carinii, and the development of a rare tumour, Kaposi’s sarcoma.

Development of AIDS can take over 15 years from infection. Following infection and seroconversion there is a latent period that is largely aclinical.

Although the latent period is aclinical there is an extensive amount of viral destruction and replication; and also destruction and replacement of CD4 T cells.

However, there is a gradual net loss of CD4 T cells, leading eventually to immunosuppression and the development of opportunistic infections, which are fatal without treatment.

HIV infection induces cellular depletion and early abnormalities of CD4+ T cells; decreases CD8+ T-cell counts and function (cellular immunity); causes deterioration of specific antigen responses (humoral immunity); and leads to alteration of innate immunity through impairment of cytolytic activity and cytokine production by natural killer cells.

Most successful HIV chemotherapy is triple therapy with a combination of reverse transcriptase inhibitors and viral protease inhibitors. However, this therapy has significant side-effects, is difficult to comply with and very expensive. Suppresses but does not clear HIV due to Vif blocking Inteferon path

HIV vaccines are faced with the problem of the high mutation rate of the virus and logistical problems of testing the efficacy of a vaccine against a chronic infection.

Microbiocides or inhibit Pyroptosis might be a way forward? Mutation rate effects?

76
Q
A